Serologicals Corporation Completes Activation of Donor Center Automation System

Apr 10, 2001, 01:00 ET from Serologicals Corporation

    ATLANTA, April 10 /PRNewswire/ -- Serologicals Corporation (Nasdaq: SERO)
 today announced that its donor center automation system -- Plasma Center
 Module 2000 (P2K) -- is fully operational within its donor center network
 throughout the United States. The online system provides the Company with
 state-of-the-art automation and tracking of its specialty antibody collection
 operations. The implementation of the system also integrates several other
 Serologicals systems, including its Central Testing Laboratory, as well as
 product management, regulatory affairs, information systems and sales.
     With P2K fully operational, Serologicals is able to track and process
 donors and antibody collections, starting from the time a donor enters one of
 the Company's donor centers, and continuing through all processes leading to
 the sale and disposition of the collected products throughout its national
 network on a real-time basis. This includes donor screening, required testing,
 U.S. and international regulatory compliance, quality assurance and inventory
 management.
     David A. Dodd, president and chief executive officer, said, "The complete
 activation of P2K throughout our national donor center network significantly
 enhances the efficiency, precision and quality within our operational
 infrastructure. This state-of-the-art system is just another example of how
 Serologicals 'delivers on its commitment' with respect to serving our valued
 customers."
     Serologicals' partner in designing, implementing and training for the P2K
 system is Fifth Dimension Information Systems Inc. ( www.5d.ca ). The Canada-
 based company is an international leader in the provision of software
 solutions to the commercial plasma industry, as well as other entities in the
 regulated healthcare field.
     "With the completion of the P2K project, we will be able to better serve
 our customers," said Dwain Wilcox, vice president, information systems. "The
 implementation of P2K marks a significant milestone in our company's
 progression toward integrated enterprise systems.  The P2K system and the
 other integrated systems provide a platform for Serologicals to improve
 productivity, information management, and customer service and will complement
 our efforts to maintain superior quality and compliance."
     Serologicals Corporation is a worldwide provider of biological products to
 life science companies.  The Company's products are used in the further
 development of diagnostic, vaccine and therapeutic products.  The company
 provides value-added, antibody-based products that are used as the active
 ingredients in therapeutic products for the treatment and management of
 diseases such as Rh incompatibility in newborns, rabies and hepatitis and in
 diagnostic products such as blood typing reagents and diagnostic test kits.
 Through its protein fractionation facility, Serologicals Corporation provides
 a variety of proteins used in the manufacturing of diagnostic reagents and
 tissue culture media components for use as additives in biotech products.
 
 

SOURCE Serologicals Corporation
    ATLANTA, April 10 /PRNewswire/ -- Serologicals Corporation (Nasdaq: SERO)
 today announced that its donor center automation system -- Plasma Center
 Module 2000 (P2K) -- is fully operational within its donor center network
 throughout the United States. The online system provides the Company with
 state-of-the-art automation and tracking of its specialty antibody collection
 operations. The implementation of the system also integrates several other
 Serologicals systems, including its Central Testing Laboratory, as well as
 product management, regulatory affairs, information systems and sales.
     With P2K fully operational, Serologicals is able to track and process
 donors and antibody collections, starting from the time a donor enters one of
 the Company's donor centers, and continuing through all processes leading to
 the sale and disposition of the collected products throughout its national
 network on a real-time basis. This includes donor screening, required testing,
 U.S. and international regulatory compliance, quality assurance and inventory
 management.
     David A. Dodd, president and chief executive officer, said, "The complete
 activation of P2K throughout our national donor center network significantly
 enhances the efficiency, precision and quality within our operational
 infrastructure. This state-of-the-art system is just another example of how
 Serologicals 'delivers on its commitment' with respect to serving our valued
 customers."
     Serologicals' partner in designing, implementing and training for the P2K
 system is Fifth Dimension Information Systems Inc. ( www.5d.ca ). The Canada-
 based company is an international leader in the provision of software
 solutions to the commercial plasma industry, as well as other entities in the
 regulated healthcare field.
     "With the completion of the P2K project, we will be able to better serve
 our customers," said Dwain Wilcox, vice president, information systems. "The
 implementation of P2K marks a significant milestone in our company's
 progression toward integrated enterprise systems.  The P2K system and the
 other integrated systems provide a platform for Serologicals to improve
 productivity, information management, and customer service and will complement
 our efforts to maintain superior quality and compliance."
     Serologicals Corporation is a worldwide provider of biological products to
 life science companies.  The Company's products are used in the further
 development of diagnostic, vaccine and therapeutic products.  The company
 provides value-added, antibody-based products that are used as the active
 ingredients in therapeutic products for the treatment and management of
 diseases such as Rh incompatibility in newborns, rabies and hepatitis and in
 diagnostic products such as blood typing reagents and diagnostic test kits.
 Through its protein fractionation facility, Serologicals Corporation provides
 a variety of proteins used in the manufacturing of diagnostic reagents and
 tissue culture media components for use as additives in biotech products.
 
 SOURCE  Serologicals Corporation